Staging cardiac damage in patients with aortic regurgitation
Autores da FMUP
Participantes de fora da FMUP
- Silva, G
- Queiros, P
- Silva, M
- Ribeiro, J
Unidades de investigação
Abstract
The impact of "downstream" pathophysiological cardiac consequences in aortic regurgitation patients were not well established. The aim of our study was to validate a staging system built for severe aortic stenosis in a large real-world cohort of aortic regurgitation (AR) patients, evaluating the prevalence of different stages of cardiac damage and assess its prognostic impact. Clinical, echocardiographic and outcome data of patients with moderate-severe AR who underwent transthoracic echocardiography between January/2014 and September/2019 were retrospectively analysed. Patients were classified according to the extent of cardiac damage: Stage 0 (no cardiac damage), Stage 1 (left ventricular damage), Stage 2 (mitral valve or left atrial damage), Stage 3 (tricuspid valve or pulmonary artery vasculature damage) and Stage 4 (right ventricular damage). The primary endpoint was all-cause mortality. A total of 571 patients (median age 73, 51% male) were enrolled: Stage 0 (14.0%), Stage 1 (21.5%), Stage 2 (49.2%), Stage 3 (12.3%) and Stage 4 (3.0%). Median follow-up time was 39.5 months (IQR 22.2 to 61.0). At the end of follow-up, cumulative death was significantly higher in more advanced disease stages (log-rank p < 0.001). On multivariable analysis, Stage 3-4 was associated with increased risk of all-cause mortality (HR 3.20; 95% CI 1.48-6.93; p = 0.003). Our study suggests that extra-valvular damage is common in patients with significant AR and that a staging system developed for aortic stenosis also provides prognostic information in these patients. This staging system may be helpful for clinical decision-making regarding the time of valvular intervention. [GRAPHICS] .
Dados da publicação
- ISSN/ISSNe:
- 1569-5794, 1573-0743
- Tipo:
- Article
- Páginas:
- 2645-2653
- Link para outro recurso:
- www.scopus.com
International Journal of Cardiovascular Imaging Springer Netherlands
Citações Recebidas na Web of Science: 2
Citações Recebidas na Scopus: 7
Documentos
- Não há documentos
Filiações
Keywords
- Aortic regurgitation; Aortic valve; Heart valve disease; Staging
Campos de estudo
Financiamento
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Screening of Fabry Disease in Portuguese Patients With Idiopathic Cardiomyopathies (F-CHECK) - NCT05409846
Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes
Estudo Observacional Académico (F-CHECK) . Sanofi . 2022
The Impact of Obesity on Cardiac Function and Morphology in Aortic Stenosis
Investigador Principal: Ricardo Manuel Alves Monteiro Fontes de Carvalho
Estudo Clínico Académico (Obesity) . 2020
Suboptimal control of cardiovascular risk factors in myocardial infarction survivors
Investigador Principal: Ricardo Manuel Alves Monteiro Fontes de Carvalho
Estudo Clínico Académico (myocard) . 2020
Impacto dos acessos femorais guiados por ecografia vs fluoroscopia nas complicações vasculares associadas à implantação de válvula aórtica percutânea
Investigador Principal: Francisco Pedro Morais Dias de Almeida Sampaio
Estudo Clínico Académico . 2021
Cardiovascular Impact of Metabolic Syndrome: From Mechanisms to New Treatment Targets
Investigador Principal: Ricardo Manuel Alves Monteiro Fontes de Carvalho
Estudo Clínico Académico . 2021
Citar a publicação
Silva G,Queiros P,Silva M,Saraiva F,Barros A,Ribeiro J,Fontes R,Sampaio F. Staging cardiac damage in patients with aortic regurgitation. Int. J. Card. Imaging. 2022. 38. (12):p. 2645-2653. IF:2,100. (3).